Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10536MR)

This product GTTS-WQ10536MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ10536MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6133MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CP-675
GTTS-WQ651MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ6366MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ1613MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ5168MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ11648MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ4365MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ12856MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW